299 related articles for article (PubMed ID: 25632182)
1. Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease.
Qiu LX; Chen T
World J Gastroenterol; 2015 Jan; 21(4):1099-107. PubMed ID: 25632182
[TBL] [Abstract][Full Text] [Related]
2. Natural Compounds with Aldose Reductase (AR) Inhibition: A Class of Medicative Agents for Fatty Liver Disease.
Wang T; Xu ZH
Comb Chem High Throughput Screen; 2023; 26(11):1929-1944. PubMed ID: 36655533
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
[TBL] [Abstract][Full Text] [Related]
4. Natural Aldose Reductase Inhibitor: A Potential Therapeutic Agent for Non-alcoholic Fatty Liver Disease.
Qiu L; Guo C
Curr Drug Targets; 2020; 21(6):599-609. PubMed ID: 31589122
[TBL] [Abstract][Full Text] [Related]
5. Apigenin protects against alcohol-induced liver injury in mice by regulating hepatic CYP2E1-mediated oxidative stress and PPARα-mediated lipogenic gene expression.
Wang F; Liu JC; Zhou RJ; Zhao X; Liu M; Ye H; Xie ML
Chem Biol Interact; 2017 Sep; 275():171-177. PubMed ID: 28803762
[TBL] [Abstract][Full Text] [Related]
6. Betaine prevented fructose-induced NAFLD by regulating LXRα/PPARα pathway and alleviating ER stress in rats.
Ge CX; Yu R; Xu MX; Li PQ; Fan CY; Li JM; Kong LD
Eur J Pharmacol; 2016 Jan; 770():154-64. PubMed ID: 26593707
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of aldose reductase ameliorates alcoholic liver disease by activating AMPK and modulating oxidative stress and inflammatory cytokines.
Shi C; Wang Y; Gao J; Chen S; Zhao X; Cai C; Guo C; Qiu L
Mol Med Rep; 2017 Sep; 16(3):2767-2772. PubMed ID: 28677809
[TBL] [Abstract][Full Text] [Related]
8. Adzuki bean ameliorates hepatic lipogenesis and proinflammatory mediator expression in mice fed a high-cholesterol and high-fat diet to induce nonalcoholic fatty liver disease.
Kim S; Hong J; Jeon R; Kim HS
Nutr Res; 2016 Jan; 36(1):90-100. PubMed ID: 26773785
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of aldose reductase ameliorates diet-induced nonalcoholic steatohepatitis in mice via modulating the phosphorylation of hepatic peroxisome proliferator-activated receptor α.
Chen T; Shi D; Chen J; Yang Y; Qiu M; Wang W; Qiu L
Mol Med Rep; 2015 Jan; 11(1):303-8. PubMed ID: 25333350
[TBL] [Abstract][Full Text] [Related]
10. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
Miura K; Ohnishi H
World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
[TBL] [Abstract][Full Text] [Related]
11. Protective Effect of Fuzi Lizhong Decoction against Non-alcoholic Fatty Liver Disease via Anti-inflammatory Response through Regulating p53 and PPARG Signaling.
Yang J; Ma W; Mei Q; Song J; Shu L; Zhang S; Li C; An L; Du N; Shi Z
Biol Pharm Bull; 2020; 43(11):1626-1633. PubMed ID: 33132309
[TBL] [Abstract][Full Text] [Related]
12. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML
Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341
[TBL] [Abstract][Full Text] [Related]
13. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
[TBL] [Abstract][Full Text] [Related]
14. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update.
Sutti S; Bruzzì S; Albano E
Expert Rev Gastroenterol Hepatol; 2016; 10(2):243-53. PubMed ID: 26634783
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
16. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
[TBL] [Abstract][Full Text] [Related]
17. Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats.
Yang ZR; Wang HF; Zuo TC; Guan LL; Dai N
BMC Pharmacol Toxicol; 2016 Apr; 17():16. PubMed ID: 27075663
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M
World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139
[TBL] [Abstract][Full Text] [Related]
19. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
Yao J; Zhou CS; Ma X; Fu BQ; Tao LS; Chen M; Xu YP
World J Gastroenterol; 2014 Oct; 20(39):14430-41. PubMed ID: 25339829
[TBL] [Abstract][Full Text] [Related]
20. Ameliorative effects of lutein on non-alcoholic fatty liver disease in rats.
Qiu X; Gao DH; Xiang X; Xiong YF; Zhu TS; Liu LG; Sun XF; Hao LP
World J Gastroenterol; 2015 Jul; 21(26):8061-72. PubMed ID: 26185377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
